A cytomegalovirus peptide-specific antibody alters natural killer cell homeostasis and ss shared in several autoimmune diseases.
erythematosus (SLE) (Hervier et al., 2011) , and primary Sjögren's syndrome 10 (pSS) (Izumi et al., 2006) . However, the mechanism of the reduction of 
18
Human cytomegalovirus (hCMV), a ubiquitous beta-herpesvirus, has been 19 reported to be associated with several autoimmune diseases (Pak et al., 1988; 20 Lunardi et al., 2006; Lunardi et al., 2000; Söderberg-Nauclér, 2012; Halenius 21 and Hengel, 2014; Barzilai et al., 2007; Igoe and Scofield, 2013; Varani and 22 Landini, 2011). However, a clear association between hCMV seroprevalence 23 and disease has thus far been difficult to establish, because hCMV is 24 widespread, whereas specific autoimmune diseases are relatively rare 25 1 inducing autoimmune disorders remains unclear.
2
In the present study, we identified an autoantibody that is induced by the 
Results

11
Identification of hCMV peptide-specific IgG (anti-Pp150) common to 12 several autoimmune diseases 13 The general association between hCMV and several autoimmune diseases led 14 us to hypothesize that there might be a common unknown mechanism 15 involved in the pathogenesis of these diseases. We first screened a random 16 12-mer peptide library against pooled immunoglobulin Gs (IgGs) derived from 17 three autoimmune disease groups (10 patients each with RA, SLE, or pSS).
18
Sixty positive phage clones were identified by enzyme-linked immunosorbent 19 assay (ELISA), and then subjected to nucleotide sequencing. Three peptides 20 that specifically bound to all pooled IgGs were isolated from the library.
21
Sequence analysis showed that the isolated peptides contained a common 22 consensus motif: KSGTGPQ (Table S1) . 23 We searched for homologous sequences of this motif in a protein data bank 24 (Swiss-Prot database). The motif aligned with amino acid residues 1012 to Rb-anti-Pp150 and Hu-anti-Pp150 specifically recognized a protein band 7 corresponding to the Pp150 protein ( Figure 1A) . The total protein of hCMV 8 particle was prepared and detected by anti-Pp150. One specific band between 9 130 kD and 170 kD was observed ( Figure 1B) . Moreover, we detected hCMV 10 infected and uninfected CCC-HPF-1 cells using anti-Pp150. We found that the 11 hCMV infected cells were positively stained by anti-Pp150 ( Figure 1C ).
12
To identify whether this motif is recognized by the antibodies of patients with 13 autoimmune diseases, the heptapeptide Pp1501012-1018 was screened against 14 a panel of serum samples. We found that Pp1501012-1018 was recognized by
15
IgG in the sera from 41 of 102 (40.2%) patients with SLE, 39 of 90 (43.3%) 16 patients with pSS, and 54 of 127 patients (42.5%) with RA. In contrast, only 4 17 of 46 (8.7%) patients with osteoarthritis (OA), and 6 of 101 (6.0%) healthy 18 controls exhibited serum IgG reactivity against Pp1501012-1018 ( Figure 1D ).
19
Compared with control groups (healthy donors and patients with OA), the 20 sensitivity and specificity of the antibody to Pp1501012-1018 in the autoimmune 21 disease group (SLE, pSS, and RA) were 41.7% and 91.8%, respectively, with 22 an area under the receiver operating curve of 0.763 (95% confidence interval, 23 0.722-0.805; P < 0.0001; Figure 1E ). Thus, a substantial proportion of 24 patients across a range of autoimmune diseases shared the antibody 25 (anti-Pp150) that exhibited significant reactivity to this CMV-derived peptide 1 motif. Based on these results, we proposed that hCMV infection can induce a 2 pathogenic antibody that is enriched in the context of autoimmune diseases. anti-Pp150, peripheral white blood cells isolated from healthy donors were 6 probed with F(ab')2 of Rb-anti-Pp150 by flow cytometry, and only CD56 bright NK 7 cells bound to the antibody (Figure 2A, Figure S1 ). to the plasma membrane of NK-92 cells ( Figure 2E ).
22
The cancerous inhibitor of PP2A (CIP2A) as a target autoantigen 23 The target was precipitated from the plasma membrane protein of NK-92 cells 24 using Rb-anti-Pp150. The specific immunoprecipitated product, with an 25 apparent molecular weight of approximately 100 kDa in sodium dodecyl 1 sulfate-polyacrylamide gel electrophoresis, was identified to be the cancerous 2 inhibitor of PP2A (CIP2A) by mass spectrometry (Figure S2A,B) . CIP2A has 3 been identified as a single-pass membrane protein that inhibits PP2A and 4 stabilizes MYC in human malignancies (Junttila et al., 2007; Junttila and 5 Westermarck , 2008).
6
Supporting these results, the immunoprecipitated band pulled down by 7 anti-Pp150 IgG was recognized by anti-CIP2A monoclonal antibody ( Figure   8 3A). Given that anti-Pp150 only bound to the CD56 bright subset, we first 9 detected the expression of CIP2A in the two subsets of human circulating NK 10 cells. CIP2A was expressed in the CD56 bright subset, but was not detected in 11 the CD56 dim NK cells (Figure 3B,C) . The sub-cellular locations of CIP2A in 12 NK-92 cells, CD56 bright and CD56 dim NK cells were detected using anti-CIP2A.
13
We found that CIP2A was expressed on cell membrane and cytoplasm in 14 NK-92 cells and CD56 bright subset but not in CD56 dim NK cells ( Figure S2C ).
15
We further performed ELISA to analyze the interaction between Rb-anti-Pp150 Figure 3E, Figure S2D ).
22
We further detected the interaction between Hu-anti-Pp150 and CIP2A by 23 ELISA. Hu-anti-Pp150 purified from the patients' sera could also specifically 24 recognize CIP2A, whereas control IgG did not ( Figure 3F) . Moreover, the 25 interaction between Hu-anti-Pp150 and CIP2A was inhibited by the 1 Pp1501012-1018 peptide in a concentration-dependent manner ( Figure 3G) . The 2 amino acid sequence of the CIP2A protein did not match that of Pp1501012-1018, 3 suggesting that Pp1501012-1018 might be a mimotope that has a similar structure 4 with the epitope of CIP2A. The number of circulating NK cells has been reported to be decreased in 7 patients with autoimmune diseases (Schleinitz et al., 2010) . Therefore, we 
3
Given its capacity to directly bind to CD56 bright NK cells, we surmised that 4 overproduction of anti-Pp150 might lead to the reduction of CD56 bright NK cells 5 in serum + patients. First, we verified that anti-Pp150 had no effect on the cell 6 cycle of NK-92 cells ( Figure S3F ) and was unable to induce cell death even (Table S2) . However, no significant difference was observed in the positive 16 rate between patients with autoimmune diseases and healthy controls. that human antigen CD13 may be associated with hCMV particle and then 24 induces the production of autoantibody against CD13 (Soderberg et al.,1996; 25 1 immunogenic during the infection, it might contribute to the production of 2 autoantibodies.
In this study, most of sera samples (99%) from patients with autoimmune 4 disease contained IgG antibodies against hCMV. However, anti-Pp150 was 5 detected in the sera from some patients but not in all infected individuals. We 6 assumed that there should be some uncovered mechanisms which are 7 responsible for the production of the autoantibody. Human antibodies against Pp1501012-1018 were purified from anti-Pp1501012-1018 9 positive patient sera with the Pp1501012-1018 peptide immunoaffinity column.
10
ADCC assay
11 NK-92 cell lines were incubated with Hu-anti-Pp150 (10 g/ml) for 30 minutes.
12
Human whole IgG was used as an isotype control. PBMC were isolated from software. P values < 0.05 were considered significant (*, P < 0.05; **, P < 0.01; 9 NS, not significant). All data are presented as means ± SD. Arnon, T.I., Achdout, H., Levi, O., Markel, G., Saleh, N., Katz, G., Gazit, R., Bogdanow, B., Weisbach, H., von Einem, J., Straschewski, S., Voigt, S., Frulloni, L., Lunardi, C., Simone, R., Dolcino, M., Scattolini, C., Falconi, M., Hervier, B., Beziat, V., Haroche, J., Mathian, A., Lebon, P., Ghillani-Dalbin, P., Izumi, Y., Ida, H., Huang, M., Iwanaga, N., Tanaka, F., Aratake, K., Arima, K., Junttila, M.R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Lunardi, C., Dolcino, M., Peterlana, D., Bason, C., Navone, R., Tamassia, N., Rayner, L.E., Kadkhodayi-Kholghi, N., Heenan, R.K., Gor, J., Dalby, P.A., Ther. 14, 101.
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YTFHPKSGTGPQ Peptide1
Common consensus motif of the three isolated phage-displayed peptides 
